These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7858736)

  • 1. Impaired natural killer cytotoxicity in peripheral blood mononuclear cells in Graves' disease.
    Marazuela M; Vargas JA; Alvarez-Mon M; Albarrán F; Lucas T; Durántez A
    Eur J Endocrinol; 1995 Feb; 132(2):175-80. PubMed ID: 7858736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer and natural killer-like cell activity of peripheral blood and intrathyroidal mononuclear cells from patients with Graves' disease.
    Tezuka H; Eguchi K; Fukuda T; Otsubo T; Kawabe Y; Ueki Y; Matsunaga M; Shimomura C; Nakao H; Ishikawa N
    J Clin Endocrinol Metab; 1988 Apr; 66(4):702-7. PubMed ID: 3257969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro production of interferon-gamma by peripheral blood from patients with Graves' disease, Hashimoto's thyroiditis and rheumatoid arthritis.
    Matsubayashi S; Akasu F; Kasuga Y; Snow K; Keystone E; Volpé R
    Clin Exp Immunol; 1990 Oct; 82(1):63-8. PubMed ID: 1976464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depressed natural killer activity in Graves' disease and during antithyroid medication.
    Wang PW; Luo SF; Huang BY; Lin JD; Huang MJ
    Clin Endocrinol (Oxf); 1988 Feb; 28(2):205-14. PubMed ID: 3168307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cell activity in patients with Graves' disease and Hashimoto's thyroiditis.
    Wenzel BE; Chow A; Baur R; Schleusener H; Wall JR
    Thyroid; 1998 Nov; 8(11):1019-22. PubMed ID: 9848716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressed natural killer cell activity in patients with euthyroid Graves' ophthalmopathy.
    Pedersen BK; Perrild H; Feldt-Rasmussen U; Christensen T; Klarlund K; Hansen JM
    Autoimmunity; 1989; 2(4):291-8. PubMed ID: 2491612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defect of a subpopulation of natural killer immune cells in Graves' disease and Hashimoto's thyroiditis: normalizing effect of dehydroepiandrosterone sulfate.
    Solerte SB; Precerutti S; Gazzaruso C; Locatelli E; Zamboni M; Schifino N; Bonacasa R; Rondanelli M; Taccani D; Ferrari E; Fioravanti M
    Eur J Endocrinol; 2005 May; 152(5):703-12. PubMed ID: 15879355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells.
    Corrales JJ; López A; Ciudad J; Mories MT; Miralles JM; Orfao A
    J Endocrinol; 1997 Dec; 155(3):491-500. PubMed ID: 9487994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial analysis of the effects of methimazole or radical therapy on circulating CD16/56 subpopulations in Graves' disease.
    Rojano J; Sasián S; Gavilán I; Aguilar M; Escobar L; Girón JA
    Eur J Endocrinol; 1998 Sep; 139(3):314-6. PubMed ID: 9758442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthyroxinemic mice have reduced natural killer cell activity. Evidence for a defective trigger mechanism.
    Stein-Streilein J; Zakarija M; Papic M; McKenzie JM
    J Immunol; 1987 Oct; 139(7):2502-7. PubMed ID: 3498760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of circulating T gamma/delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease.
    Bossowski A; Urban M; Stasiak-Barmuta A
    Pediatr Res; 2003 Sep; 54(3):425-9. PubMed ID: 12761360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
    Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective response of natural killer activity to thyroxine in Graves' disease.
    Lee MS; Hong WS; Hong SW; Lee JO; Kang TW
    Korean J Intern Med; 1990 Jul; 5(2):93-6. PubMed ID: 2098098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NKG2A expression and impaired function of NK cells in patients with new onset of Graves' disease.
    Zhang Y; Lv G; Lou X; Peng D; Qu X; Yang X; Ayana DA; Guo H; Jiang Y
    Int Immunopharmacol; 2015 Jan; 24(1):133-9. PubMed ID: 25281394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and antibody mediated cytotoxicity in autoimmune thyroid disease.
    Bogner U; Wall JR; Schleusener H
    Acta Endocrinol Suppl (Copenh); 1987; 281():133-8. PubMed ID: 3475896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of peripheral blood natural killer cell activity by excess thyroid hormone.
    Papic M; Stein-Streilein J; Zakarija M; McKenzie JM; Guffee J; Fletcher MA
    J Clin Invest; 1987 Feb; 79(2):404-8. PubMed ID: 3492513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CD16 (Fc receptor III) and interleukin-2 in the reactivation of natural killer cells after inhibitory target cell contact.
    Heiskala M; Ståhls A; Seppälä I; Timonen T
    Nat Immun Cell Growth Regul; 1991; 10(5):265-77. PubMed ID: 1836835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cell mediated cytotoxicity of tumor cells initiated by neem leaf preparation is associated with CD40-CD40L-mediated endogenous production of interleukin-12.
    Bose A; Baral R
    Hum Immunol; 2007 Oct; 68(10):823-31. PubMed ID: 17961770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes of peripheral mononuclear cell subpopulations in autoimmune thyroid diseases].
    Tanaka T
    Nihon Naibunpi Gakkai Zasshi; 1985 Jul; 61(7):711-23. PubMed ID: 2998893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 4 (IL-4) blocks the IL-2-induced increased in natural killer activity and DNA synthesis of decidual CD16-CD56bright NK cells by inhibiting expression of the IL-2 receptor alpha, beta, and gamma.
    Saito S; Umekage H; Nishikawa K; Morii T; Narita N; Enomoto M; Sakakura S; Harada N; Ichijo M; Morikawa H
    Cell Immunol; 1996 May; 170(1):71-7. PubMed ID: 8660801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.